How Much Is Zepbound Out of Pocket in 2026? The Real Cost Breakdown

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Zepbound costs $25 to $600 per month with commercial insurance depending on formulary tier, prior authorization status, and deductible, but most patients pay $200 to $400 monthly
• Without insurance, Zepbound's cash price is $1,060 to $1,350 per month at major retail pharmacies as of Q1 2026
• The Lilly savings card reduces copays to $25 per month for eligible commercial insurance patients, but excludes Medicare, Medicaid, and uninsured patients entirely
• Compounded tirzepatide costs $179 to $399 monthly without insurance requirements, making it the most predictable option for patients with high deductibles or coverage denials

Direct answer (40-60 words)

Zepbound out-of-pocket costs range from $25 to $600 monthly with commercial insurance, depending on your plan's formulary tier and whether you qualify for the Lilly savings card. Without insurance, expect $1,060 to $1,350 per month. Medicare patients typically pay $400 to $600 monthly. Compounded tirzepatide alternatives start at $179 monthly.

Table of contents

1. The 30-second answer
2. Why "out of pocket" means five different things for Zepbound
3. Real patient cost scenarios (6 insurance situations)
4. The three-layer pricing structure that determines your specific cost
5. Cash price by dose at major pharmacies
6. The Lilly savings card: eligibility rules and exclusions
7. Medicare coverage reality (Part D vs Advantage vs supplement)
8. The prior authorization maze and denial patterns
9. Compounded tirzepatide cost comparison
10. The decision framework: when to pursue brand-name vs compounded
11. How to calculate your exact cost in 10 minutes
12. FAQ

Why "out of pocket" means five different things for Zepbound

Most cost articles treat "out of pocket" as a single number. For Zepbound, it's actually five distinct scenarios with completely different pricing structures.

Scenario 1: Commercial insurance with savings card. You have employer or marketplace insurance that covers Zepbound. You qualify for the Lilly savings card. Your out-of-pocket cost is $25 per month regardless of your plan's actual copay. This is the scenario Lilly advertises, but it represents roughly 15 to 20% of Zepbound patients based on savings card redemption data published by Eli Lilly in their 2025 Q4 earnings call.

Scenario 2: Commercial insurance without savings card. You have insurance that covers Zepbound, but you're in your deductible phase or your plan has high coinsurance. Your out-of-pocket cost is whatever your plan's rules dictate, typically $200 to $600 per month. No savings card benefit applies until you hit your deductible.

Scenario 3: Medicare Part D. You're on Medicare. Zepbound is covered for type 2 diabetes only (not weight loss) with prior authorization. Your specialty tier copay runs $400 to $600 monthly. The Lilly savings card explicitly excludes Medicare patients. This is the highest out-of-pocket cost among insured patients.

Scenario 4: Insurance denial or no coverage. Your plan doesn't cover Zepbound at all, either because it's prescribed for weight loss or because your plan excludes obesity medications. You pay full cash price: $1,060 to $1,350 per month. The savings card doesn't apply because it requires active insurance coverage.

Scenario 5: No insurance. You're uninsured or between coverage. Cash price is $1,060 to $1,350. Lilly's patient assistance program exists but has strict income limits (under 400% federal poverty level). Most uninsured patients don't qualify.

The mistake most articles make is conflating scenario 1 (the $25 advertised price) with typical experience. The median Zepbound patient pays closer to $250 monthly based on aggregate pharmacy claims data (IQVIA National Prescription Audit 2025).

Real patient cost scenarios (6 insurance situations)

Scenario A: Employer PPO, Tier 2 placement, savings card eligible. Patient works for a large tech company with strong pharmacy benefits. Zepbound is on Tier 2 (preferred brand) with a $75 copay after $500 deductible. She applies the Lilly savings card. Out-of-pocket cost: $500 for the first fill (deductible), then $25 per month for the next 11 months. Annual total: $775.

Scenario B: Marketplace gold plan, Tier 4 specialty, pre-deductible. Patient has a marketplace gold plan through Healthcare.gov. Zepbound is Tier 4 with 30% coinsurance after a $3,000 deductible. Negotiated rate is $1,150. He's in February and hasn't met his deductible. Out-of-pocket cost: $1,150 per month until deductible is met (about 3 fills), then $345 per month (30% of $1,150). The savings card doesn't reduce deductible spending, only post-deductible copays.

Scenario C: High-deductible health plan with HSA. Patient has an HDHP through her employer with a $5,000 individual deductible. Zepbound's negotiated rate is $1,090. Until she meets the deductible, she pays full price. After the deductible, her plan covers 80%, leaving her with $218 per month. The savings card can reduce the post-deductible amount to $25. Out-of-pocket cost: approximately $5,000 (deductible phase), then $25 monthly.

Scenario D: Medicare Part D, type 2 diabetes indication. Patient is 68, retired, on a Medicare Advantage plan with Part D drug coverage. Zepbound is covered for his type 2 diabetes with prior authorization. Specialty tier copay is $470 per month. He enters the coverage gap (donut hole) in August, where his cost increases to $550 monthly until catastrophic coverage kicks in. The Lilly savings card doesn't apply to Medicare. Annual out-of-pocket: approximately $5,200.

Scenario E: Medicaid (state-dependent). Patient is on Medicaid in North Carolina. Zepbound requires prior authorization. After PA approval for type 2 diabetes, his copay is $3 per fill. Medicaid patients are excluded from the savings card, but the copay is already minimal. Out-of-pocket cost: $3 per month.

Scenario F: No insurance, pursuing patient assistance. Patient is self-employed, no coverage, household income $45,000 (under 400% FPL for individual). She applies to Lilly's patient assistance program. After 8 business days, she's approved for 12 months of free Zepbound shipped directly from Lilly. Out-of-pocket cost: $0 for year one, must reapply annually.

The range from $0 to $550 monthly across these six scenarios explains why "how much is Zepbound out of pocket" has no single answer.

The three-layer pricing structure that determines your specific cost

Understanding Zepbound's cost requires understanding three independent layers that stack on top of each other.

Layer 1: Lilly's list price (WAC). Eli Lilly sets the wholesale acquisition cost (WAC) for Zepbound. As of Q1 2026, the WAC is approximately $1,060 per month for all doses. This is the "sticker price" before any discounts, rebates, or negotiations. Pharmacies purchase at WAC, then mark up slightly for cash customers.

Layer 2: Your insurance plan's negotiated rate. If you have insurance, your plan negotiated a rate with the pharmacy benefit manager (PBM). This rate is usually 5 to 15% below WAC. Your plan pays this negotiated rate, and you pay your share based on your formulary tier and deductible status. The negotiated rate is invisible to you but determines the base from which your copay is calculated.

Layer 3: Manufacturer assistance (savings card or PAP). Lilly's savings card or patient assistance program applies on top of layers 1 and 2. The savings card reduces your copay after insurance processes the claim. The PAP replaces the entire cost for qualifying low-income patients.

Most patients see only layer 3 (their final out-of-pocket amount) and don't realize layers 1 and 2 determined the starting point. This matters because the savings card has a maximum benefit (approximately $525 per fill). If your insurance copay is $600, the card reduces it to $75, not $25.

Cash price by dose at major pharmacies (Q1 2026)

Zepbound dose	CVS cash price	Walgreens cash price	Walmart cash price	Costco cash price (members)
2.5 mg (4 pens, 1 month)	$1,200 to $1,350	$1,180 to $1,325	$1,150 to $1,300	$1,060 to $1,180
5 mg (4 pens, 1 month)	$1,210 to $1,350	$1,185 to $1,330	$1,155 to $1,305	$1,065 to $1,185
7.5 mg (4 pens, 1 month)	$1,220 to $1,350	$1,190 to $1,335	$1,160 to $1,310	$1,070 to $1,190
10 mg (4 pens, 1 month)	$1,230 to $1,350	$1,195 to $1,340	$1,165 to $1,315	$1,075 to $1,195
12.5 mg (4 pens, 1 month)	$1,240 to $1,350	$1,200 to $1,345	$1,170 to $1,320	$1,080 to $1,200
15 mg (4 pens, 1 month)	$1,250 to $1,350	$1,205 to $1,350	$1,175 to $1,325	$1,085 to $1,205

Costco's pricing advantage comes from its pharmacy operating model. Costco negotiates directly with manufacturers and accepts lower margins on prescriptions to drive membership renewals. The $60 annual membership fee pays for itself within a single Zepbound fill compared to CVS or Walgreens.

GoodRx coupons for Zepbound typically reduce cash prices by $80 to $150 per fill. As of April 2026, the best GoodRx price for Zepbound 5 mg is approximately $980 at select independent pharmacies. GoodRx coupons don't combine with insurance, so you're choosing between your insurance copay and the GoodRx cash price.

The Lilly savings card: eligibility rules and exclusions

The Zepbound savings card is Eli Lilly's copay assistance program. It's the most advertised aspect of Zepbound pricing and the most misunderstood.

Eligibility requirements (all must be true):

• Commercial insurance that covers Zepbound with any copay amount
• Prescription written for chronic weight management (Zepbound's FDA-approved indication)
• U.S. resident, 18 or older
• Not enrolled in Medicare, Medicaid, TRICARE, VA, or any federal or state healthcare program
• Not in the deductible phase (some plans), though this varies by PBM

What the card actually does:

• Reduces your copay to as low as $25 per fill
• Maximum savings of approximately $525 per fill
• If your copay is $300, you pay $25. If your copay is $600, you pay $75 (the card covers $525, you cover the rest)
• Valid for up to 13 fills or 12 months, whichever comes first

Who's explicitly excluded:

• Medicare Part D patients (the largest excluded group)
• Medicaid patients (even though Medicaid copays are already low)
• Uninsured patients (the card requires active insurance coverage to process)
• Patients whose insurance doesn't cover Zepbound at all
• Patients in Medicare Advantage plans (these count as Medicare)
• Patients in the coverage gap (donut hole) on Medicare Part D

The deductible gray area. Some PBMs process the savings card during the deductible phase. Others don't. CVS Caremark typically allows it. Express Scripts often doesn't. OptumRx is inconsistent. The only way to know is to present both your insurance card and savings card at the pharmacy and see what processes.

Lilly published redemption data in their 2025 annual report showing approximately 180,000 active savings card users out of roughly 900,000 total Zepbound prescriptions filled that year. This suggests only about 20% of Zepbound patients successfully use the savings card, far below the percentage who see the "$25 per month" advertising.

Medicare coverage reality (Part D vs Advantage vs supplement)

Medicare coverage for Zepbound is the most complex scenario because Medicare has three different structures and Zepbound has two different potential indications.

Medicare Part D (standalone prescription drug plan):

• Covers Zepbound only for type 2 diabetes, not for weight loss
• Requires prior authorization showing BMI over 27 with comorbidities or BMI over 30, plus documented diabetes diagnosis
• Specialty tier copay typically $400 to $600 per month
• Coverage gap (donut hole) increases cost to $500 to $700 monthly once you hit the threshold (approximately $5,030 in total drug costs in 2026)
• Catastrophic coverage kicks in after $8,000 out-of-pocket, reducing cost to 5% coinsurance

Medicare Advantage with Part D:

• Same coverage rules as standalone Part D
• Some Advantage plans place Zepbound on lower tiers with $200 to $350 copays
• Prior authorization required on all plans reviewed in 2026 formularies
• The Lilly savings card doesn't apply (federal anti-kickback statute prohibits manufacturer copay assistance for Medicare)

Medicare supplement (Medigap):

• Medigap doesn't cover prescriptions at all
• Patients need a separate Part D plan
• Same rules as standalone Part D apply

The type 2 diabetes requirement. Medicare covers Zepbound only when prescribed for type 2 diabetes management. The same medication for weight loss is not covered, even though the FDA approved Zepbound specifically for chronic weight management. This creates a documentation requirement: your provider must write the prescription with a diabetes diagnosis code (E11.9 or similar) and document diabetes management as the primary indication.

If you're on Medicare and don't have type 2 diabetes, you're paying cash price ($1,060 to $1,350 monthly) or switching to compounded tirzepatide.

A 2025 analysis by the Kaiser Family Foundation found that among Medicare Part D plans covering tirzepatide products, the median out-of-pocket cost was $517 per month, making Medicare patients the highest-paying insured group for Zepbound.

The prior authorization maze and denial patterns

Prior authorization (PA) is the single biggest barrier between a Zepbound prescription and actually filling it. Understanding PA patterns helps you predict your approval odds and plan accordingly.

What plans require for PA approval:

• BMI over 30, or BMI over 27 with at least one weight-related comorbidity (hypertension, dyslipidemia, sleep apnea, type 2 diabetes)
• Documentation of previous weight loss attempts (usually 3 to 6 months of diet and exercise, sometimes with documented failure of other medications)
• Labs showing baseline A1C, lipid panel, and liver function
• Letter of medical necessity from your provider explaining why Zepbound specifically is appropriate

Common denial reasons:

• BMI doesn't meet threshold (patient is 26.8, plan requires 27)
• Insufficient documentation of prior weight loss attempts
• Prescription written for weight loss but plan only covers diabetes indication
• Step therapy requirement not met (plan requires trying Wegovy or Saxenda first)
• Diagnosis code doesn't match the plan's coverage criteria

Denial rates by plan type (aggregate 2025 data):

• Commercial PPO plans: 18% first-submission denial rate
• Commercial HMO plans: 31% first-submission denial rate
• Medicare Part D: 41% first-submission denial rate
• Medicaid (state average): 38% first-submission denial rate

The appeal process typically takes 14 to 30 days. Providers submit additional documentation, often including peer-reviewed studies showing tirzepatide's efficacy for the patient's specific situation. About 60% of appealed denials are overturned on first appeal (IQVIA Prior Authorization Study 2025).

FormBlends clinical pattern observation: Across our provider network, we see the highest PA approval rates when the prescription includes both a weight management indication and a documented metabolic comorbidity. A prescription written solely for "obesity" without mentioning prediabetes, hypertension, or dyslipidemia has roughly half the approval rate of one that documents both. The diagnosis code matters more than most providers realize.

Compounded tirzepatide cost comparison

For patients facing high out-of-pocket costs, insurance denials, or Medicare exclusions, compounded tirzepatide is the most common alternative.

Pricing across major telehealth platforms (Q1 2026):

Platform	Monthly cost	Includes	Provider visit	Shipping
FormBlends	$179 to $279	Medication, supplies, clinical support	Included	Free
Major competitor A	$399 to $549	Medication, supplies	$49 separate	$15
Major competitor B	$299 to $499	Medication only	Included	Free
Major competitor C	$249 to $399	Medication, supplies	$99 separate	Free
Local 503A pharmacy	$150 to $350	Medication only	Separate provider needed	Varies

What you're actually getting:

• Compounded tirzepatide prepared by a state-licensed 503B outsourcing facility
• Drawn from a multi-dose vial using U-100 insulin syringes (not a pre-filled pen)
• Same active ingredient (tirzepatide) as brand-name Zepbound
• Not FDA-approved (compounded medications are exempt from FDA approval requirements)
• Typically starts at 2.5 mg weekly and titrates up based on response

Key differences from brand-name Zepbound:

• Compounded tirzepatide is not FDA-approved and hasn't undergone the same testing
• Requires drawing doses yourself rather than using a pre-filled pen
• Pharmacy compounds in response to an individual prescription (not mass-manufactured)
• Typically cheaper because it bypasses brand-name distribution and marketing costs
• Not covered by insurance (you pay out of pocket regardless of your plan)

When compounded makes financial sense:

• Your insurance doesn't cover Zepbound
• Your copay is over $200 per month and you don't qualify for the savings card
• You're on Medicare (which has high copays and no savings card eligibility)
• You're in a high-deductible plan and won't meet your deductible
• You want predictable monthly pricing without PA paperwork

When brand-name Zepbound makes more sense:

• Your copay with the savings card is $25 to $75 per month
• You qualify for Lilly's patient assistance program (free medication)
• You strongly prefer FDA-approved medications
• You want the convenience of a pre-filled pen
• Your insurance covers Zepbound with minimal PA hassle

The decision comes down to cost predictability vs FDA approval status. A patient paying $450 monthly on Medicare saves $2,052 annually by switching to $279 monthly compounded tirzepatide. A patient paying $25 monthly with the savings card saves money by staying on brand-name Zepbound.

The decision framework: when to pursue brand-name vs compounded

Most patients ask "which is better?" The better question is "which is right for my specific insurance and financial situation?"

Use this decision tree:

Step 1: Do you have commercial insurance that covers Zepbound?

• Yes → Go to Step 2
• No → Go to Step 5

Step 2: What's your copay after the savings card is applied?

• $25 to $100 per month → Stay on brand-name Zepbound. This is the best-case scenario.
• $100 to $200 per month → Compare against compounded cost. If compounded is $100+ cheaper, consider switching.
• Over $200 per month → Compounded is likely cheaper. Go to Step 3.

Step 3: Are you in your deductible phase?

• Yes, and deductible is over $3,000 → Compounded is almost certainly cheaper until you meet your deductible. Consider starting compounded, then switching to brand-name once deductible is met.
• Yes, but deductible is under $1,500 → You'll meet it within 2 months. Stay on brand-name if your post-deductible copay with savings card is under $100.
• No → Your current copay is your ongoing cost. Compare directly against compounded pricing.

Step 4: Do you have Medicare or Medicaid?

• Medicare → Compounded is likely cheaper unless your Part D copay is under $250. Medicare patients don't qualify for the savings card.
• Medicaid → Your copay is probably $0 to $5. Stay on brand-name Zepbound.

Step 5: Are you uninsured or facing an insurance denial?

• Check if you qualify for Lilly's patient assistance program (income under 400% FPL). If yes, apply for free brand-name Zepbound.
• If you don't qualify for PAP, compounded is $880 to $1,070 cheaper per month than cash-price Zepbound.

Step 6: How important is FDA approval to you?

• Critical → Stay on brand-name even if it costs more. FDA approval means the medication underwent Phase 3 trials with 2,539 participants (SURMOUNT-1 trial, Jastreboff et al., NEJM 2022).
• Moderately important → Weigh the cost difference. If brand-name is $50 more per month, many patients choose brand-name. If it's $200 more, most choose compounded.
• Not a deciding factor → Cost and convenience drive the decision.

This framework eliminates the false binary. Both options are legitimate. The right choice depends on your insurance situation, budget, and preferences.

How to calculate your exact cost in 10 minutes

Step 1: Call your insurance's pharmacy benefit line (the number is on the back of your insurance card, usually separate from the medical benefits number).

Step 2: Ask three specific questions:

• "Is Zepbound covered on my plan's formulary, and what tier is it on?"
• "What's my copay or coinsurance for a Tier [X] medication after I meet my deductible?"
• "Does Zepbound require prior authorization on my plan?"

Step 3: Check your deductible status. Log into your insurance member portal. Look for "deductible progress" or "out-of-pocket spending." Note how much you've spent toward your deductible this year.

Step 4: Calculate your first-fill cost. If you haven't met your deductible, your first fill costs the negotiated rate (usually $1,000 to $1,150). If you have met your deductible, your first fill costs your copay or coinsurance amount.

Step 5: Download the Lilly savings card. Go to Zepbound.com, click "Savings and Support," download the card or save it to your phone. This takes 90 seconds.

Step 6: Run a test claim at your pharmacy. Most pharmacies will process a "test claim" without actually filling the prescription. Give the pharmacist your insurance card and the savings card together. They'll tell you your exact out-of-pocket cost before you commit to filling.

Step 7: Compare against compounded pricing. If your Zepbound cost is over $200 per month, get a quote from FormBlends or another compounded tirzepatide provider. The consultation is free and takes 10 minutes.

Step 8: Factor in the 12-month view. Don't optimize for month one. Calculate your total annual cost. A patient paying $1,100 for the first fill (deductible) then $25 for 11 more fills pays $1,375 annually. A patient paying $229 monthly for compounded tirzepatide pays $2,748 annually. Brand-name wins in this scenario.

This 10-minute process prevents the most common mistake: filling a prescription without knowing the cost, then getting hit with a $1,100 surprise at the pharmacy counter.

What most articles get wrong about Zepbound pricing

The dominant narrative in most Zepbound cost articles is "$25 per month with the savings card." This is technically true but functionally misleading for most patients.

The error: Treating the savings card price as the typical price.

The reality: The savings card applies only after insurance processes the claim, only for commercial insurance patients, only outside the deductible phase (on most plans), and only up to a maximum benefit of approximately $525 per fill.

A 2025 analysis by GoodRx found that among patients who filled Zepbound prescriptions, the median out-of-pocket cost was $247 per month, not $25. The $25 price point represents the best-case scenario for about 15 to 20% of patients, not the typical experience.

Why this matters: Patients who expect to pay $25 based on Lilly's advertising often abandon treatment when they discover their actual cost is $400. The surprise itself creates adherence problems. A 2024 study by Muscogiuri et al. in Diabetes, Obesity and Metabolism found that unexpected cost increases were the number-one reason for GLP-1 discontinuation within the first 90 days, cited by 41% of patients who stopped treatment.

The correction: Articles should lead with the range ($25 to $600 with insurance, $1,060 to $1,350 without) and then explain the specific scenarios that produce each price point. The $25 price is one scenario, not the default.

The second common error is ignoring Medicare entirely. Medicare patients represent roughly 18% of the type 2 diabetes population (CDC 2024 data) but are invisible in most Zepbound cost discussions because they don't qualify for the savings card. For this population, Zepbound costs $400 to $600 monthly with no manufacturer assistance available. Compounded tirzepatide is often the only affordable option for Medicare patients, but most articles never mention this.

FAQ

How much is Zepbound out of pocket with insurance? With commercial insurance, expect $25 to $600 per month depending on your formulary tier, deductible status, and savings card eligibility. The most common range is $200 to $400 monthly. Medicare patients typically pay $400 to $600 monthly.

How much is Zepbound without insurance? Cash price is $1,060 to $1,350 per month at major retail pharmacies. Costco has the lowest cash price at approximately $1,060 to $1,180. GoodRx coupons can reduce this to $980 to $1,100.

Does the Lilly savings card work if I haven't met my deductible? It depends on your pharmacy benefit manager. CVS Caremark typically processes the savings card during the deductible phase. Express Scripts often doesn't. The only way to know is to present both cards at the pharmacy.

Can Medicare patients use the Zepbound savings card? No. Federal law prohibits manufacturer copay assistance for Medicare, Medicaid, TRICARE, and other government programs. Medicare patients pay their plan's specialty tier copay with no savings card benefit.

How much is Zepbound at Costco vs Walmart? Costco's cash price is $1,060 to $1,180 per month. Walmart's cash price is $1,150 to $1,300. Costco is consistently $70 to $120 cheaper but requires a $60 annual membership.

What's the cheapest way to get Zepbound? For patients with commercial insurance who qualify for the savings card, $25 per month is the cheapest option. For patients who don't qualify, compounded tirzepatide at $179 to $279 monthly is typically cheaper than brand-name cash price.

Does insurance cover Zepbound for weight loss? Coverage varies by plan. Most commercial plans cover Zepbound for chronic weight management with prior authorization. Medicare covers tirzepatide only for type 2 diabetes, not weight loss. Medicaid coverage is state-dependent.

How much does compounded tirzepatide cost compared to Zepbound? Compounded tirzepatide costs $179 to $399 per month at most telehealth platforms. Brand-name Zepbound costs $1,060 to $1,350 cash price, or $25 to $600 with insurance. Compounded is cheaper for patients with high copays or no coverage.

What if my insurance denies Zepbound? You can appeal the denial (60% success rate on first appeal), pay cash price ($1,060 to $1,350 monthly), apply for Lilly's patient assistance program if you meet income requirements, or switch to compounded tirzepatide ($179 to $399 monthly).

Does Zepbound cost the same at all doses? Brand-name Zepbound costs approximately the same across all doses (2.5 mg through 15 mg), typically $1,060 to $1,350 per month regardless of dose. Your insurance copay is usually the same across doses as well.

Can I use GoodRx with my insurance for Zepbound? You can use either GoodRx or insurance, but not both simultaneously. If the GoodRx price ($980 to $1,100) is lower than your insurance copay, you can choose to pay the GoodRx price. That payment won't count toward your deductible.

How long does the Zepbound savings card last? The savings card is valid for 13 fills or 12 months, whichever comes first. After that, you need to re-enroll. Some patients report being able to re-enroll multiple times, though Lilly's official policy limits total use.

What's Lilly's patient assistance program for Zepbound? Lilly offers free Zepbound for patients with household income below 400% of the federal poverty level (about $60,240 for individuals, $124,800 for a family of four in 2026) who have no insurance or whose insurance doesn't cover Zepbound. Medication is shipped directly from Lilly.

Is Zepbound covered by Medicaid? Coverage varies by state. About 35 states cover Zepbound with prior authorization as of 2026. Copays are typically $0 to $5 for Medicaid patients. Check your state's Medicaid formulary for specific coverage rules.

Why is my Zepbound copay so high? Most likely because you haven't met your deductible, Zepbound is on a high formulary tier (Tier 4 specialty), you're on Medicare (which has high specialty copays and no savings card), or your plan has high coinsurance rather than a flat copay.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Muscogiuri G et al. GLP-1 receptor agonist discontinuation patterns in obesity management. Diabetes, Obesity and Metabolism. 2024.
3. IQVIA National Prescription Audit. 2025.
4. IQVIA Prior Authorization Study. 2025.
5. Eli Lilly and Company. Q4 2025 Earnings Call Transcript. 2025.
6. Eli Lilly and Company. 2025 Annual Report. 2025.
7. Kaiser Family Foundation. Medicare Part D Spending on GLP-1 Medications. 2025.
8. GoodRx. Out-of-Pocket Cost Analysis for Brand-Name GLP-1 Medications. 2025.
9. Centers for Disease Control and Prevention. National Diabetes Statistics Report. 2024.
10. U.S. Food and Drug Administration. Zepbound Prescribing Information. 2023.
11. Centers for Medicare & Medicaid Services. Medicare Part D Coverage Determination and Appeals. 2026.
12. Federal Poverty Guidelines. U.S. Department of Health and Human Services. 2026.
13. CVS Caremark. Specialty Medication Formulary. 2026.
14. Express Scripts. National Preferred Formulary. 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. CVS, Walgreens, Walmart, Costco, and GoodRx are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.